223 related articles for article (PubMed ID: 31752059)
1. Development of Non-Immunosuppressive FK506 Derivatives as Antifungal and Neurotrophic Agents.
Jung JA; Yoon YJ
J Microbiol Biotechnol; 2020 Jan; 30(1):1-10. PubMed ID: 31752059
[TBL] [Abstract][Full Text] [Related]
2. Biosynthesis of Nonimmunosuppressive FK506 Analogues with Antifungal Activity.
Beom JY; Jung JA; Lee KT; Hwangbo A; Song MC; Lee Y; Lee SJ; Oh JH; Ha SJ; Nam SJ; Cheong E; Bahn YS; Yoon YJ
J Nat Prod; 2019 Aug; 82(8):2078-2086. PubMed ID: 31321978
[TBL] [Abstract][Full Text] [Related]
3. The biosynthetic pathway of FK506 and its engineering: from past achievements to future prospects.
Ban YH; Park SR; Yoon YJ
J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):389-400. PubMed ID: 26342319
[TBL] [Abstract][Full Text] [Related]
4. Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies.
Gold BG; Udina E; Bourdette D; Navarro X
Neurol Res; 2004 Jun; 26(4):371-80. PubMed ID: 15198862
[TBL] [Abstract][Full Text] [Related]
5.
Lee Y; Lee KT; Lee SJ; Beom JY; Hwangbo A; Jung JA; Song MC; Yoo YJ; Kang SH; Averette AF; Heitman J; Yoon YJ; Cheong E; Bahn YS
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181374
[TBL] [Abstract][Full Text] [Related]
6. Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs.
Gobeil SM; Bobay BG; Juvvadi PR; Cole DC; Heitman J; Steinbach WJ; Venters RA; Spicer LD
mBio; 2021 Dec; 12(6):e0300021. PubMed ID: 34809463
[TBL] [Abstract][Full Text] [Related]
7. Chemical and biological characterization of two FK506 analogs produced by targeted gene disruption in Streptomyces sp. MA6548.
Shafiee A; Motamedi H; Dumont FJ; Arison BH; Miller RR
J Antibiot (Tokyo); 1997 May; 50(5):418-23. PubMed ID: 9207912
[TBL] [Abstract][Full Text] [Related]
8. A calcineurin antifungal strategy with analogs of FK506.
Nambu M; Covel JA; Kapoor M; Li X; Moloney MK; Numa MM; Soltow QA; Trzoss M; Webb P; Webb RR; Mutz M
Bioorg Med Chem Lett; 2017 Jun; 27(11):2465-2471. PubMed ID: 28412204
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein.
Odom A; Del Poeta M; Perfect J; Heitman J
Antimicrob Agents Chemother; 1997 Jan; 41(1):156-61. PubMed ID: 8980772
[TBL] [Abstract][Full Text] [Related]
10. Neuroimmunophilin ligands: the development of novel neuroregenerative/ neuroprotective compounds.
Gold BG; Villafranca JE
Curr Top Med Chem; 2003; 3(12):1368-75. PubMed ID: 12871168
[TBL] [Abstract][Full Text] [Related]
11. Identity of immunosuppressant FR-900520 with ascomycin.
Morisaki M; Arai T
J Antibiot (Tokyo); 1992 Jan; 45(1):126-8. PubMed ID: 1372308
[No Abstract] [Full Text] [Related]
12. Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants.
Sierra-Paredes G; Sierra-Marcuño G
CNS Neurosci Ther; 2008; 14(1):36-46. PubMed ID: 18482098
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a cell model based on FKBP12 dimerization for screening of FK506-like neurotrophic small molecular compounds.
Xiao H; Wang LL; Shu CL; Yu M; Li S; Shen BF; Li Y
J Biomol Screen; 2006 Apr; 11(3):225-35. PubMed ID: 16490780
[TBL] [Abstract][Full Text] [Related]
14. FKBP12-Dependent Inhibition of Calcineurin Mediates Immunosuppressive Antifungal Drug Action in
Ianiri G; Applen Clancey S; Lee SC; Heitman J
mBio; 2017 Oct; 8(5):. PubMed ID: 29066552
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
Del Poeta M; Cruz MC; Cardenas ME; Perfect JR; Heitman J
Antimicrob Agents Chemother; 2000 Mar; 44(3):739-46. PubMed ID: 10681348
[TBL] [Abstract][Full Text] [Related]
16. FK506 and its analogs - therapeutic potential for neurological disorders.
Klettner A; Herdegen T
Curr Drug Targets CNS Neurol Disord; 2003 Jun; 2(3):153-62. PubMed ID: 12769796
[TBL] [Abstract][Full Text] [Related]
17. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506.
Gold BG; Densmore V; Shou W; Matzuk MM; Gordon HS
J Pharmacol Exp Ther; 1999 Jun; 289(3):1202-10. PubMed ID: 10336507
[TBL] [Abstract][Full Text] [Related]
18. The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation.
Quintá HR; Galigniana MD
Br J Pharmacol; 2012 May; 166(2):637-49. PubMed ID: 22091865
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of FK506 for experimental temporal lobe epilepsy.
Nishimura T; Imai H; Minabe Y; Sawa A; Kato N
Neurosci Res; 2006 Dec; 56(4):386-90. PubMed ID: 16989915
[TBL] [Abstract][Full Text] [Related]
20. A new assay method for immunosuppressants with a tacrolimus (FK506)-like mode of action.
Sakamoto K; Izumi S; Miyauchi M; Okuhara M
J Antibiot (Tokyo); 1995 Jul; 48(7):727-9. PubMed ID: 7544337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
